DaVita Clinical Research (DCR), a provider of clinical research services focused on kidney research as well as specialty therapeutics, has completed its phase I-IIa clean room to comply with USP 797 high risk regulations. DCR ensures its ability to handle compounds in a safe and efficient manner.

“The purpose of the clean room and the USP 797 guidelines is to reduce infection risks to patients where compound sterile preparations are prepared, as well as to protect pharmacy staff,” stated DCR vice president of clinical services Amy Young. “Many clinical facilities are struggling to fully comply with this regulation. We are dedicated to delivering superior clinical results. The achievement of the USP 797 standard demonstrates this dedication and DCR’s commitment to our patients.”